Retrieved from Tortelli, B
Baseline considerations it lists include an A1C above 7.5 percent, BMI, kidney function and cardiovascular disease status
Even a 0.5% reduction in A1c is considered clinically meaningful, as it can lower the risk of heart disease and other complications of T2D, such as kidney and nerve damage, so that level of reduction particularly on top of existing recommended treatment is a win
In non-diabetic individuals with overweight or obesity, with an average BMI of approximately 38, liraglutide administered at a dose of 3.0 mg per day for 56 weeks resulted in an 8% weight loss [10]
Visibly Lifts and Sculpts: Strengthens skins support network to help contour and lift sagging areas
No long-term animal studies have been performed to evaluate the carcinogenic potential of levocarnitine